| Dear shareholders, good morning, good afternoon, and good evening!Let's quickly eat a melon.On March 12, 2026, GRAIL, a leader in multi-cancer early detection, issued an announcement.CEO of the companyBob Ragusa, aged 66,Will retire on June 1, 2026, and step down from the position of Chief Executive Officer.Bob joined GRAIL in 2021 and served as COO (Chief Operating Officer) at Illumina from 2013 to 2021.In addition, he also serves as a director of Twist Biosciences.His retirement at this time easily leads to the association that it is for the aforementioned reason.NHSClinical failure, leading to a sharp drop in stock price.GRAIL Board Appoints President Josh Ofman, M.D., M.H.S., as CEO of GRAIL Following Ragusa's RetirementIn addition, Ofman has been appointed as a member of the GRAIL board of directors, effective immediately.Dear blind students, you may not have experienced any changes up to this point.So, if I tell you that from 2020 to 2021, Josh Ofman's position at GRAIL was CMO (Chief Medical Officer).Moreover, the NHS-Galleri clinical study was launched in September 2021, and it is speculated that Josh was likely the person who approved the clinical trial protocol at that time.Anyway, I can't understand it, and I don't mean to stand up for Bob.After all, I don't deserve it. Bob's salary in 2024 is approximately $7.6 million, while Josh's salary is approximately $5.8 million.Well, I'd better go and do some manual labor.Oh, by the way, I couldn't help it, but the CEO of GRAIL is quite high-risk.Including Bob, there have been 6 CEOs in 10 years.Especially from 2016 to 2019, GRAIL went through four CEO changes in just four years.It has a bit of the flavor of the South Korean president...As of the time of writing, GRAIL's stock price fell by 4.8%.Let's save tomorrow's melon for tomorrow, and adjourn the meeting! | 
